Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3544 - ATTRACTION-04 (ONO-4538-37): A Randomized, Multicenter, Phase 2/3 Study of Nivolumab (Nivo) Plus chemotherapy in Patients (Pts) with Previously Untreated Advanced or Recurrent Gastric (G) or Gastroesophageal Junction (GEJ) Cancer

Date

09 Sep 2017

Session

Poster display session

Presenters

Li-Tzong Chen

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

L. Chen1, Y. Kang2, M. Tanimoto3, N. Boku4

Author affiliations

  • 1 National Institute Of Cancer Research, National Health Research Institutes, and National Cheng Kung University Hospital,, 704 - Tainan/TW
  • 2 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 3 Oncology Clinical Development Planning, Ono pharmaceutical co.,led., 541-8564 - Osaka/JP
  • 4 Gastrointestinal Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
More

Resources

Abstract 3544

Background

Nivo, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor, has demonstrated survival benefits across a number of tumor types. In ATTRACTION-02 (ONO-4538-12), a double-blind, placebo-controlled, Phase 3 study in pts with unresectable advanced or recurrent G/GEJ cancer refractory to or intolerant of standard therapy, Nivo monotherapy (3 mg/kg Q2W) demonstrated survival benefits (overall survival [OS] and progression free survival [PFS]) vs. placebo and a manageable safety profile (Yoon-Koo Kang, et al. 2017 ASCO Gastrointestinal Cancers Symposium). The combination fluoropyrimidine and platinum is the current standard-of-care (SOC) in the first-line treatment of pts with metastatic G/GEJ cancer that generally achieves a median survival ranging between 11 and 13 months. Therefore, new treatment options are needed to further improve the clinical outcomes of this particular pts population. This multinational, randomized, Phase 2/3 trial will evaluate the efficacy and safety of Nivo plus chemotherapy (S-1 + oxaliplatin [SOX] or capecitabine + oxaliplatin [CapeOX]) as first-line therapy for pts with unresectable advanced or recurrent G/GEJ cancer (ATTRACTION-04; NCT02746796).

Trial design

This trial consists of two parts. The part 1 is a randomized, open-label study to assess the feasibility of Nivo in combination with the first-line chemotherapy, either SOX or CapeOX. In part 2, approximately 650 chemo-naïve pts aged ≥ 20 years with ECOG PS 0-1, and HER2 negative unresectable or recurrent G/GEJ cancer will be randomized to receive chemotherapy (SOX or CapeOX, investigator’s choice) plus either Nivo or Placebo. Randomization will be stratified by intensity of PD-L1 expression, ECOG PS score, disease status and geographical region. Primary endpoints are PFS assessed by independent radiological review committee (IRRC) and OS. Secondary endpoints include objective response rate and disease control rate assessed by IRRC and the site investigator, and duration of response and time to response assessed by IRRC. The part 2 study was started in February 2017.

Clinical trial identification

NCT02746796

Legal entity responsible for the study

ONO Pharmaceutical Co., Ltd

Funding

ONO Pharmaceutical Co., Ltd Bristol-Myers Squibb

Disclosure

L-T. Chen: ONO Pharmaceutical Co., Ltd, Eli Lilly, MSD, PharmaEngine, Merrimack, TTY, Syncore, Five Prime, Novartis, GSK, Merck Serono, Polaris, anti-alpha enolase (ENO-1) monoclonal antibody/HuniLife. Y-K. Kang: Ono Pharmaceutical. Co., Ltd. Bristol-Myers Squibb, Lilly, ImClone, Taiho Pharmaceutical, Roche, Genentech, Novartis, Bayer. M. Tanimoto: ONO Pharmaceutical Co., Ltd. N. Boku: Ono, Taiho, Chugai, Eli-Lily.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.